Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 14/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 5/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6504671 | 1.00 | EPHX1 (0.51) | EPHX1KDM4EALDH1A1EPHX2NPC1 | |
| SCHEMBL10249415 | 0.86 | EPHX1 (0.34) | EPHX1KDM4EALDH1A1EPHX2NPC1 | |
| SCHEMBL6427758 | 0.85 | NAAA (0.41) | EPHX1KDM4EALDH1A1EPHX2NPC1 | |
| SCHEMBL6390166 | 0.85 | NAAA (0.38) | EPHX1KDM4EALDH1A1EPHX2NPC1 | |
| SCHEMBL6502409 | 0.83 | EPHX1 (0.37) | EPHX1ALDH1A1EPHX2NPC1RAB9A | |
| SCHEMBL6509220 | 0.82 | NPC1 (0.48) | EPHX1KDM4EALDH1A1NPC1RAB9A | |
| SCHEMBL6499847 | 0.81 | RAB9A (0.36) | EPHX1ALDH1A1NPC1TP53TSHR | |
| SCHEMBL6509241 | 0.81 | KMT2A (0.36) | EPHX1KDM4EALDH1A1EPHX2NPC1 | |
| SCHEMBL6505116 | 0.81 | S1PR2 (0.39) | EPHX1KDM4EALDH1A1EPHX2NPC1 | |
| SCHEMBL1605232 | 0.80 | SLC29A1 (0.34) | EPHX1KDM4ENPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050239853-A1 | New compounds | BIOVITRUM AB (SE) | 2005-10-27 | — | — | US | claimed |
| US-20050239853-A1 | New compounds | BIOVITRUM AB (SE) | 2005-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239853-A1 | New compounds | HSD11B1, CYP11B1, HSD3B1 | EPHX1 299/4885KDM4E 2824/4885ALDH1A1 67/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.